Results 261 to 270 of about 85,285 (279)
Some of the next articles are maybe not open access.
Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis
Journal of Cellular Physiology, 2022AbstractMany patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients.
Habib Yaribeygi +5 more
openaire +2 more sources
Sodium–glucose co-transporter-2 inhibitors
2022Abstract This chapter studies the use of aldosterone antagonists, also known as Mineralocorticoid Receptor Antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction (LVSD) — now called heart failure with reduced ejection fraction (HF-REF) — have ...
Matthew M. Y. Lee +2 more
openaire +1 more source
Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure
The American Journal of Cardiology, 2019Sodium-glucose co-transporter 2 (SGLT2) receptors are primarily located in the proximal convoluted tubule of the nephron. These receptors are responsible for almost 90% to 95% of tubular reabsorption of the glucose in the nephron. In patients with diabetes mellitus, due to upregulation of SGLT2 receptors, glucose reabsorption is further increased.
Raktim K. Ghosh +8 more
openaire +3 more sources
Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering
Current Drug Targets, 2018Diabetes is an important cause of morbidity and mortality worldwide. Management of blood glucose is critical for diabetic patients since diabetes carries a risk for many diseases and disorders. Although there are several antidiabetic agents in the markets for a long time, some of the agents have dose-limiting side effects, such as hypoglycemia and ...
Ceylan, Asli F., Ren, Sidney Y.
openaire +3 more sources
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors
New Zealand Medical Journal, 2022The sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure ...
Chok G, Chan, Ralph, Stewart
openaire +2 more sources
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
European Journal of Pharmacology, 2021Nonalcoholic fatty liver disease (NAFLD) is considered the most prevalent chronic hepatic disease, as it has been estimated that one of four individuals in the general population has been affected by NAFLD. The evolution of the referred entity, which includes nonalcoholic steatohepatitis (NASH) and hepatic fibrosis, may have crucial and even fatal ...
Evangelia S. Makri +2 more
openaire +2 more sources
Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
Clinical Nephrology, 2017Chronic kidney disease among patients with diabetes is on the rise. The sodium glucose co-transporters 2 inhibitors are a new class of glucose-lowering agents, which act through a novel mechanism by producing a decline in glucose reabsorption in the kidney, thereby increasing glucosuria and decreasing serum glucose levels.
Natalia G, Vallianou +2 more
openaire +2 more sources
Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
Expert Opinion on Therapeutic Patents, 2012Maintenance of glucose homeostasis in healthy individuals involves SGLT2 (sodium glucose co-transporter 2)-mediated recovery of glucose from the glomerular filtrate which otherwise would be excreted in urine. Clinical studies indicate that SGLT2 inhibitors provide an insulin-independent means to reduce the hyperglycemia that is the hallmark of type 2 ...
openaire +2 more sources
Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes
Expert Opinion on Emerging Drugs, 2013Type 2 diabetes mellitus (T2DM) is a public health challenge globally. Numerous treatments are available which can improve insulin sensitivity or stimulate its secretion including biguanides, sulphonylureas and glitazones, as well as insulin, GLP-1 agonists and DPP-IV inhibitors.
Luke D, Boyle, John P H, Wilding
openaire +2 more sources
A safety update on sodium glucose co‐transporter 2 inhibitors
Diabetes, Obesity and Metabolism, 2019Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering agent to be shown to reduce cardiovascular events. They are generally well tolerated with infrequent serious adverse events. The most frequent side effect is genital mycotic infections with candida species that are usually mild to moderate in severity, easily ...
openaire +2 more sources